StreetInsider.com News Articles

Rhelion unit expands psilocybin supply deal for Italian clinical trial

Fri, 25 Sep 2026 08:49:16 -0400

Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX0) (OTCQB: TRUFF) announced that its wholly owned subsidiary, Filament Health Corp., has expanded a supply and licence agreement with the University G. d'Annunzio of Chieti-Pescara in Italy to provide additional quantities of its botanical psilocybin drug candidate, PEX010, for a clinical trial targeting treatment-resistant depression.

The trial, called TEMPO, was authorized under the European Union Clinical Trials Regulation with EU CT number 2025-523346-27-00. During the regulatory review process, the number of trial participants was increased, prompting the expansion of the supply agreement to provide additional PEX010 25 mg capsules. Filament also provides regulatory

Rhelion unit expands psilocybin supply deal for Italian clinical trial

Fri, 25 Sep 2026 08:49:16 -0400

Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Expands Supply Agreement with the University of Chieti-Pescara for PEX010 in the TEMPO Clinical Trial of Psilocybin for Treatment-Resista

Fri, 25 Sep 2026 08:48:00 -0400

Following authorization of the TEMPO trial under the European Union Clinical Trials Regulation, Filament has expanded its supply agreement with the University G. d'Annunzio of Chieti-Pescara to support an increase in the number of trial participants.

Toronto, Ontario--(Newsfile Corp. - September 25, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX0) (OTCQB: TRUFF) ("Rhelion" or the "Company") an Ontario-based organization advancing innovation and research within the legal psychedelic sector. Through its wholly owned subsidiary Filament Health Corp. ("Filament"), the Company develops, manufactures and supplies PEX010, its patented, standardized, GMP manufactured botanical psilocybin drug candidate, to clinical research and compassionate access

Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Expands Supply Agreement with the University of Chieti-Pescara for PEX010 in the TEMPO Clinical Trial of Psilocybin for Treatment-Resista

Fri, 25 Sep 2026 08:48:00 -0400

Following authorization of the TEMPO trial under the European Union Clinical Trials Regulation, Filament has expanded its supply agreement with the University G. d'Annunzio of Chieti-Pescara to support an increase in the number of trial participants.

Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Expands Supply Agreement with the University of Chieti-Pescara for PEX010 in the TEMPO Clinical Trial of Psilocybin for Treatment-Resista

Fri, 25 Sep 2026 08:48:00 -0400

Following authorization of the TEMPO trial under the European Union Clinical Trials Regulation, Filament has expanded its supply agreement with the University G. d'Annunzio of Chieti-Pescara to support an increase in the number of trial participants.

Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Expands Supply Agreement with the University of Chieti-Pescara for PEX010 in the TEMPO Clinical Trial of Psilocybin for Treatment-Resista

Fri, 25 Sep 2026 08:48:00 -0400

Following authorization of the TEMPO trial under the European Union Clinical Trials Regulation, Filament has expanded its supply agreement with the University G. d'Annunzio of Chieti-Pescara to support an increase in the number of trial participants.

Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Issued New Canadian Patent, Extending the Broadest Natural Psilocybin Patent Estate

Tue, 22 Sep 2026 07:33:00 -0400

A new Canadian patent, "Psychoactive Alkaloid Extraction and Composition with Controlled Dephosphorylation," has been issued by the Canadian Intellectual Property Office, adding to the intellectual property estate behind PEX010, the standardized natural psilocybin drug candidate supporting and supplying more than 80 studies worldwide.

Toronto, Ontario--(Newsfile Corp. - September 22, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX0) (OTCQB: TRUFF) ("Rhelion" or the "Company") an Ontario-based organization advancing innovation and research within the legal psychedelic sector. Through its wholly owned subsidiary Filament Health Corp. ("Filament"), the Company develops, manufactures and supplies PEX010, its patented, standardized, GMP manufactured botanical psilocybin drug

Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Issued New Canadian Patent, Extending the Broadest Natural Psilocybin Patent Estate

Tue, 22 Sep 2026 07:33:00 -0400

A new Canadian patent, "Psychoactive Alkaloid Extraction and Composition with Controlled Dephosphorylation," has been issued by the Canadian Intellectual Property Office, adding to the intellectual property estate behind PEX010, the standardized natural psilocybin drug candidate supporting and supplying more than 80 studies worldwide.

Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Issued New Canadian Patent, Extending the Broadest Natural Psilocybin Patent Estate

Tue, 22 Sep 2026 07:33:00 -0400

A new Canadian patent, "Psychoactive Alkaloid Extraction and Composition with Controlled Dephosphorylation," has been issued by the Canadian Intellectual Property Office, adding to the intellectual property estate behind PEX010, the standardized natural psilocybin drug candidate supporting and supplying more than 80 studies worldwide.

Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Issued New Canadian Patent, Extending the Broadest Natural Psilocybin Patent Estate

Tue, 22 Sep 2026 07:33:00 -0400

A new Canadian patent, "Psychoactive Alkaloid Extraction and Composition with Controlled Dephosphorylation," has been issued by the Canadian Intellectual Property Office, adding to the intellectual property estate behind PEX010, the standardized natural psilocybin drug candidate supporting and supplying more than 80 studies worldwide.

Filament Health ships psilocybin drug to Phase 3 palliative care trial

Mon, 21 Sep 2026 07:51:14 -0400

Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX) (OTCQB: TRUFF) announced that its wholly owned subsidiary, Filament Health Corp., has shipped its botanical psilocybin drug candidate PEX010 to Bruyère Health Research Institute in Ottawa for use in a Phase 3 clinical trial.

The trial, titled "Psilocybin Microdose for Psychological and Existential Distress in Palliative Care (PSYCHED-PAL)," is a multi-site, double-blind, placebo-controlled study registered under NCT07063862. Bruyère Health Research Institute is the sponsor of the trial. Filament is not the sponsor and is not responsible for its conduct.

The study plans to enroll 120 participants experiencing psychological distress, including depression, anxiety, and loss

Filament Health ships psilocybin drug to Phase 3 palliative care trial

Mon, 21 Sep 2026 07:51:14 -0400

The study plans to enroll 120 participants experiencing psychological distress, including depression, anxiety, and loss

Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Delivers PEX010 to Bruyere Health Research Institute's Phase 3 Trial of Microdose Psilocybin in Palliative Care

Mon, 21 Sep 2026 07:49:00 -0400

Filament has shipped PEX010 to Bruyère Health Research Institute for its Phase 3 placebo-controlled trial, which follows a published Phase I/II study that found microdose psilocybin safe, feasible and potentially effective for psychological distress in people with advanced illness.

Toronto, Ontario--(Newsfile Corp. - September 21, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX) (OTCQB: TRUFF) ("Rhelion" or the "Company") an Ontario-based organization advancing innovation and research within the legal psychedelic sector. Through its wholly owned subsidiary Filament Health Corp. ("Filament"), the Company develops, manufactures and supplies PEX010, its patented, standardized, GMP manufactured botanical psilocybin drug candidate, to clinical research

Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Delivers PEX010 to Bruyere Health Research Institute's Phase 3 Trial of Microdose Psilocybin in Palliative Care

Mon, 21 Sep 2026 07:49:00 -0400

Filament has shipped PEX010 to Bruyère Health Research Institute for its Phase 3 placebo-controlled trial, which follows a published Phase I/II study that found microdose psilocybin safe, feasible and potentially effective for psychological distress in people with advanced illness.

Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Delivers PEX010 to Bruyere Health Research Institute's Phase 3 Trial of Microdose Psilocybin in Palliative Care

Mon, 21 Sep 2026 07:49:00 -0400

Filament has shipped PEX010 to Bruyère Health Research Institute for its Phase 3 placebo-controlled trial, which follows a published Phase I/II study that found microdose psilocybin safe, feasible and potentially effective for psychological distress in people with advanced illness.

Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Delivers PEX010 to Bruyere Health Research Institute's Phase 3 Trial of Microdose Psilocybin in Palliative Care

Mon, 21 Sep 2026 07:49:00 -0400

Filament has shipped PEX010 to Bruyère Health Research Institute for its Phase 3 placebo-controlled trial, which follows a published Phase I/II study that found microdose psilocybin safe, feasible and potentially effective for psychological distress in people with advanced illness.

Rhelion unit signs psilocybin supply deal with Dutch research center

Thu, 17 Sep 2026 07:54:11 -0400

Rhelion Life Sciences Corp. (CSE: RHEL, FSE: 4YX0, OTCQB: TRUFF) announced that its wholly owned subsidiary, Filament Health Corp., has entered into a supply and licensing agreement with the Centre for Human Drug Research (CHDR) in Leiden, the Netherlands.

Under the agreement, Filament will supply its botanical psilocybin drug candidate PEX010 in 1 mg and 5 mg doses, along with matching placebo capsules, for a CHDR-sponsored study examining low and medium dose psilocybin. The study is being conducted in collaboration with the PRSM Lab at Leiden University and has received funding from Norrsken Mind.

Filament will also provide regulatory support for the

Rhelion unit signs psilocybin supply deal with Dutch research center

Thu, 17 Sep 2026 07:54:11 -0400

Filament will also provide regulatory support for the

Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Signs Supply and Licensing Agreement with the Centre for Human Drug Research for PEX010 in a Study of Low and Medium Dose Psilocybin

Thu, 17 Sep 2026 07:52:00 -0400

Filament will supply PEX010 1 mg and 5 mg capsules, with matching placebo, for a study of low and medium dose psilocybin sponsored by the Centre for Human Drug Research in Leiden, the Netherlands.

Toronto, Ontario--(Newsfile Corp. - September 17, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX0) (OTCQB: TRUFF) ("Rhelion" or the "Company") an Ontario-based organization advancing innovation and research within the legal psychedelic sector. Through its wholly owned subsidiary Filament Health Corp. ("Filament"), the Company develops, manufactures and supplies PEX010, its patented, standardized, GMP manufactured botanical psilocybin drug candidate, to clinical research and compassionate access programs at

Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Signs Supply and Licensing Agreement with the Centre for Human Drug Research for PEX010 in a Study of Low and Medium Dose Psilocybin

Thu, 17 Sep 2026 07:52:00 -0400

Filament will supply PEX010 1 mg and 5 mg capsules, with matching placebo, for a study of low and medium dose psilocybin sponsored by the Centre for Human Drug Research in Leiden, the Netherlands.

Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Signs Supply and Licensing Agreement with the Centre for Human Drug Research for PEX010 in a Study of Low and Medium Dose Psilocybin

Thu, 17 Sep 2026 07:52:00 -0400

Filament will supply PEX010 1 mg and 5 mg capsules, with matching placebo, for a study of low and medium dose psilocybin sponsored by the Centre for Human Drug Research in Leiden, the Netherlands.

Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Signs Supply and Licensing Agreement with the Centre for Human Drug Research for PEX010 in a Study of Low and Medium Dose Psilocybin

Thu, 17 Sep 2026 07:52:00 -0400

Filament will supply PEX010 1 mg and 5 mg capsules, with matching placebo, for a study of low and medium dose psilocybin sponsored by the Centre for Human Drug Research in Leiden, the Netherlands.

Rhelion unit signs USC supply deal for psilocybin drug candidate

Tue, 15 Sep 2026 08:00:16 -0400

Rhelion Life Sciences Corp. (CSE: RHEL, FSE: 4YX0, OTCQB: TRUFF) announced that its wholly owned subsidiary, Filament Health Corp., has entered into a supply and licensing agreement with the University of Southern California's Keck School of Medicine for its botanical psilocybin drug candidate, PEX010.

Under the agreement, PEX010 will be supplied as the investigational drug product for a study examining whether structured mindfulness meditation training can augment psilocybin-assisted therapy, including in a clinical depression cohort. Filament is not the sponsor of the trial and is not responsible for its conduct.

PEX010 is produced using Filament's proprietary extraction, purification, and stabilization methods, which

Rhelion unit signs USC supply deal for psilocybin drug candidate

Tue, 15 Sep 2026 08:00:16 -0400

Rhelion Life Sciences Corp. (CSE: RHEL, FSE: 4YX0, OTCQB: TRUFF) announced that its wholly owned subsidiary, Filament Health Corp., has entered into a supply and licensing agreement with the University of Southern California's Keck School of Medicine for its botanical psilocybin drug candidate, PEX010.

PEX010 is produced using Filament's proprietary extraction, purification, and stabilization methods, which

Rhelion Life Sciences Wholly Owned Subsidiary Filament Health Signs Supply and Licensing Agreement with the University of Southern California for PEX010 in a Trial for Psilocybin-Assisted Mindfulness

Tue, 15 Sep 2026 07:59:00 -0400

Toronto, Ontario--(Newsfile Corp. - September 15, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX0) (OTCQB: TRUFF) ("Rhelion" or the "Company"), an Ontario-based organization advancing innovation and research within the legal psychedelic sector, is pleased to announce that its wholly owned subsidiary, Filament Health Corp. ("Filament"), has entered into a supply and licensing agreement with the University of Southern California, on behalf of its Keck School of Medicine of USC, for the supply of PEX010, Filament's patented, standardized, GMP manufactured botanical psilocybin drug candidate.

PEX010 will be supplied for Psilocybin Assisted Mindfulness Therapy.

Filament supplies PEX010 as the investigational drug product.